BELLUS Health Inc logo

BLU - BELLUS Health Inc Share Price

C$3.59 -0.1  -1.4%

Last Trade - 10/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £125.9m
Enterprise Value £81.3m
Revenue £17.2k
Position in Universe 503rd / 2675
Bullish
Bearish
Unlock BLU Revenue
Momentum
Relative Strength (%)
1m -14.5%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -78.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
2.38 4.02 1.89 0.17 0.035 0.035 0.031 0.036 -57.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, BELLUS Health Inc revenues decreased 43% to C$4K. Net loss increased from C$3.6M to C$10.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from C$2.5M to C$6.6M (expense), General/Administration increase from C$1.1M to C$2.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BLU Revenue Unlock BLU Revenue

Net Income

BLU Net Income Unlock BLU Revenue

Normalised EPS

BLU Normalised EPS Unlock BLU Revenue

PE Ratio Range

BLU PE Ratio Range Unlock BLU Revenue

Dividend Yield Range

BLU Dividend Yield Range Unlock BLU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BLU EPS Forecasts Unlock BLU Revenue
Profile Summary

BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer’s disease.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated April 12, 2012
Public Since September 15, 2014
No. of Shareholders: n/a
No. of Employees: 17
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Toronto Stock Exchange
Shares in Issue 60,392,993
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BLU Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BLU
Upcoming Events for BLU
Thursday 12th November, 2020 Estimate
Q3 2020 BELLUS Health Inc Earnings Release
Frequently Asked Questions for BELLUS Health Inc
What is the BELLUS Health Inc share price?

As of 10/08/20, shares in BELLUS Health Inc are trading at C$3.59, giving the company a market capitalisation of £125.9m. This share price information is delayed by 15 minutes.

How has the BELLUS Health Inc share price performed this year?

Shares in BELLUS Health Inc are currently trading at C$3.59 and the price has moved by -64.77% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BELLUS Health Inc price has moved by -65.27% over the past year.

What are the analyst and broker recommendations for BELLUS Health Inc?

Of the analysts with advisory recommendations for BELLUS Health Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BELLUS Health Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will BELLUS Health Inc next release its financial results?

BELLUS Health Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the BELLUS Health Inc dividend yield?

BELLUS Health Inc does not currently pay a dividend.

Does BELLUS Health Inc pay a dividend?

BELLUS Health Inc does not currently pay a dividend.

When does BELLUS Health Inc next pay dividends?

BELLUS Health Inc does not currently pay a dividend.

How do I buy BELLUS Health Inc shares?

To buy shares in BELLUS Health Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BELLUS Health Inc?

Shares in BELLUS Health Inc are currently trading at C$3.59, giving the company a market capitalisation of £125.9m.

Where are BELLUS Health Inc shares listed? Where are BELLUS Health Inc shares listed?

Here are the trading details for BELLUS Health Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: BLU
What kind of share is BELLUS Health Inc?

Based on an overall assessment of its quality, value and momentum, BELLUS Health Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BELLUS Health Inc share price forecast 2020?

Shares in BELLUS Health Inc are currently priced at C$3.59. At that level they are trading at 0.224% discount to the analyst consensus target price of 0.00.

Analysts covering BELLUS Health Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.613 for the next financial year.

How can I tell whether the BELLUS Health Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BELLUS Health Inc. Over the past six months, the relative strength of its shares against the market has been -69.21%. At the current price of C$3.59, shares in BELLUS Health Inc are trading at -66.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BELLUS Health Inc PE Ratio?

We were not able to find PE ratio data for BELLUS Health Inc.

Who are the key directors of BELLUS Health Inc?

BELLUS Health Inc's management team is headed by:

Francesco Bellini - CHM
Roberto Bellini - PRE
Franklin Berger - IND
Charles Cavell - CCH
Pierre Larochelle - IND
Martin Tolar - DRC
Francois Desjardins - VFN
Denis Garceau - SVP
Tony Matzouranis - VBD
Youssef Bennani - IND
Clarissa Desjardins - IND
Chau Khuong - IND
Sebastien Roy - SEC
Who are the major shareholders of BELLUS Health Inc?

Here are the top five shareholders of BELLUS Health Inc based on the size of their shareholding:

RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 9.09% (5.49m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 8.5% (5.14m shares)
Victoria Square Ventures Inc. Corporation
Percentage owned: 8.17% (4.94m shares)
Power Corporation of Canada Holding Company
Percentage owned: 8.17% (4.94m shares)
Rocabe Investments, Inc. Corporation
Percentage owned: 7.55% (4.56m shares)
Similar to BLU
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.